Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 20/20 | 0.51 |
| ▸ | HCRTR2 | O43614 | 20/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18197650 | 0.83 | HCRTR1 (0.44) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL16025403 | 0.83 | HCRTR2 (0.50) | HCRTR1HCRTR2CYP1A2 | |
| SCHEMBL27900612 | 0.82 | HCRTR2 (0.49) | HCRTR1HCRTR2CYP1A2CYP3A4 | |
| SCHEMBL18163352 | 0.82 | HCRTR1 (0.47) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL1586788 | 0.81 | HCRTR1 (0.51) | HCRTR1HCRTR2CYP1A2 | |
| SCHEMBL31707742 | 0.81 | HCRTR1 (0.51) | HCRTR1HCRTR2CYP1A2 | |
| SCHEMBL19604232 | 0.80 | HCRTR2 (0.48) | HCRTR1HCRTR2CYP1A2 | |
| SCHEMBL17761282 | 0.80 | HCRTR1 (0.47) | HCRTR1HCRTR2CYP1A2CYP3A4 | |
| SCHEMBL18197644 | 0.79 | HCRTR2 (0.49) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL17069769 | 0.79 | HCRTR2 (0.49) | HCRTR1HCRTR2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160318899-A1 | THIOETHER-PIPERIDINYL OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-11-03 | — | — | US | disclosed |
| US-20160318944-A1 | PIPERIDINYLOXY LACTONE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-11-03 | — | — | US | disclosed |
| US-20160016935-A1 | 2-PYRIDYLOXY-4-ETHER OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318899-A1 | THIOETHER-PIPERIDINYL OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | HCRTR1 2/4885HCRTR2 1/4885CYP1A2 2346/4885 |
| US-20160016935-A1 | 2-PYRIDYLOXY-4-ETHER OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY2R | HCRTR1 2/4885HCRTR2 1/4885CYP1A2 903/4885 |
| US-20160318944-A1 | PIPERIDINYLOXY LACTONE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, CRHR1 | HCRTR1 2/4885HCRTR2 1/4885CYP1A2 3121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.